AXA TianPing/Deep research

🎯 This summary covers AXA Tianping Property & Casualty Insurance Co., Ltd., AXA Group's wholly owned P&C insurer in China, tracing its corporate structure, business model, financial performance, and strategic trajectory across ten sections.

1. Corporate profile: AXA Tianping was founded in 2004 as Tianping Auto Insurance and became a wholly foreign-owned enterprise in December 2019 after AXA bought out its domestic joint-venture partners for RMB 4.6 billion, making it the largest 100% foreign-owned P&C insurer in China. The company operates under the NFRA-supervised C-ROSS II solvency regime with a registered capital of RMB 846 million and a national footprint spanning 25 provincial branches and 90+ sub-branches covering provinces that represent over 85% of China's GDP. Headcount has been streamlined from roughly 6,000 a decade ago to approximately 2,600 full-time employees by 2024, reflecting efficiency gains and outsourcing of non-core functions. Governance has been localized since 2022: Chairwoman Zhu Shamiao and CEO Zuo Weihao (Kevin Chor) provide strategic direction, both carrying deep regional and global AXA experience, and all senior appointments have received NFRA approval.
2. Segment overview: Motor insurance remains the largest business line but its portfolio share has fallen sharply — from over 90% of gross premiums before the strategic pivot to roughly 57% by 2025 — as the company deliberately reallocates capacity toward Health & Lifestyle and selective Commercial P&C. Non-motor lines (health, accident, property, and liability) reached approximately 43% of premiums in H1 2025, compared with just 9% in 2017, driven by short-term medical, personal accident, critical illness, and travel products enriched by AXA's global health expertise. Distribution has evolved from Tianping's legacy direct model — which already achieved one of the highest direct sales ratios in the market (41% of motor premiums via online and telemarketing) — to a true omnichannel approach that adds WeChat mini-programs, automotive and travel affinity partnerships, and a 2024 MOU with PICC for distribution and service collaboration. The agency and broker channel, managed through a wholly-owned insurance sales subsidiary, complements digital channels primarily for commercial and more complex health products, with the overall mix weighted toward cost-efficient direct and digital routes to contain acquisition costs.
3. Segment performance: Total GWP recovered from a reform-driven trough of RMB 5.94 billion in 2021 to RMB 6.74 billion in 2024, marginally exceeding pre-reform levels while carrying a materially healthier mix — motor now represents roughly 60% of GWP versus over 90% prior to the pivot. The 2020 Comprehensive Auto Insurance Reform was the principal disruptor, slashing average motor premiums by approximately 20%, compressing expense ratio caps to 25%, and temporarily spiking combined ratios above 110%; the company responded with selective underwriting, reduced acquisition costs, and accelerated diversification into health. The combined ratio has gradually improved from the ~109% five-year average to approximately 106% in 2024, with S&P projecting a further decline toward 100–105% over the subsequent two years as expense management and mix shift take hold. Health insurance has been the standout growth engine — expanding at well over 30% annually from 2022 to 2024 — and, while medical inflation and initial distribution costs present margin headwinds, health profitability is already slightly superior to motor's and is the key driver of overall combined ratio improvement.
4. Strategy priorities: AXA Tianping's strategy is organized around three pillars — diversify, digitalize, and differentiate — all anchored to AXA Group's global direction but tailored for the Chinese market. The diversification imperative is clear: management targets more than half of premiums from non-motor lines in the coming years, expanding into critical illness, high-end medical, pet, cyber, and SME packaged solutions to reduce regulatory and pricing sensitivity tied to the auto market. Digitalization is pursued through upgraded online claims systems, AI-driven fraud detection, telematics for motor pricing, cashless hospital settlement networks for health, and WeChat-native policy issuance — investments that simultaneously improve expense ratios and enable scalable growth in high-volume personal lines. Differentiating through the "Payer-to-Partner" model is the third thrust: layering telemedicine, wellness coaching, chronic disease management, second medical opinion services, and driver safety tools onto insurance products to build loyalty in a price-competitive market, drawing on AXA's global health technology assets adapted for China.
5. Income statement: AXA Tianping has posted net losses in every year from 2020 through 2024, but the trajectory is firmly positive — the net loss shrank from RMB 275.8 million in 2021 to RMB 66.2 million in 2024, placing the company on track for the projected return to net profit by 2026. Net premiums earned were broadly flat at RMB 5.5–5.6 billion across 2021–2024 as unearned premium reserve build-up from growing health business dampened earned revenue recognition even as GWP rose. Investment income provided a stable secondary revenue of approximately RMB 260–280 million annually through 2023, though it dipped to RMB 237.5 million in 2024 amid lower market yields; a one-off gain of ~RMB 50 million from the disposal of AXA Tianping Insurance Sales Co. boosted the 2023 result. Operating expenses fell in absolute terms from RMB 6.21 billion in 2021 to RMB 5.88 billion in 2024 despite premium growth — a clear efficiency signal — with the underwriting loss narrowing from approximately RMB 389 million in 2021 to roughly RMB 93 million in 2024.
6. Balance sheet: Total assets held steady in the RMB 10–12 billion range throughout 2020–2024, ending 2024 at approximately RMB 11.4 billion, with the asset mix dominated by cash and high-grade fixed income (roughly 48% government and policy bank bonds plus 30% high-grade corporate bonds) in line with AXA Group's emphasis on capital preservation over yield in emerging markets. Insurance contract liabilities — principally unearned premium reserve (RMB ~1.91 billion) and outstanding claims reserve (RMB ~2.07 billion) — represent the core liabilities, with motor bodily injury reserves carrying the longest tail and reserved conservatively. Total equity stood at approximately RMB 2.8 billion at end-2024, down from RMB ~3.2 billion in 2019 due to cumulative losses; however, a significant OCI gain of RMB 176 million in 2024 from rising bond valuations actually made total comprehensive income positive that year, partially rebuilding equity. The company carries no material financial debt beyond an inferred subordinated bond issued in 2023 to supplement Tier 2 capital, and S&P characterizes the capital position as "satisfactory" with continued AXA Group backing underpinning going-concern confidence.
7. Claims & reserving: Motor claims dominate the portfolio, with post-reform severity rising (compulsory liability limits increased to RMB 200,000 per accident) even as frequency moderated during COVID lockdowns; industry-wide motor loss ratios spiked above 70% in 2021 before returning to the mid-60% range by 2023–2024. Health claims have grown proportionally with the expanding book — medical inflation running at double-digit annual rates is a structural concern — but annual repricing of short-term health products allows AXA Tianping to track cost trends, and managed-care techniques such as preferred provider networks help contain outpatient claims. Natural catastrophe exposure is primarily auto-related (floods, typhoons), geographically diversified across 25 provinces, and protected by catastrophe excess-of-loss reinsurance cover; no single nat-cat event in 2020–2024 produced a material net impact on the financials. Reserve adequacy is certified annually by an external actuary, and the 2022 statutory report explicitly confirmed no reserve deficiencies; digital claims processing has shortened motor settlement cycles, further reducing IBNR uncertainty and supporting the clean reserving position regulators and auditors have consistently assessed as satisfactory.
8. Reinsurance: AXA Tianping maintains a protective and conservative reinsurance program, ceding approximately 10–15% of premiums annually (ceded premium around RMB 0.7–1.0 billion per year) and retaining the bulk of its high-frequency retail risk. The program combines surplus treaties for commercial lines, quota share arrangements on select motor tranches via AXA Group's internal reinsurer, and catastrophe excess-of-loss cover led by China Re with international capacity provided by AXA XL — ensuring regulatory alignment with China's preference for domestic reinsurers while accessing group expertise for large or complex risks. Per-risk XOL protection caps single large third-party liability claims, while the cat XOL treaty is calibrated to 1-in-200 year scenarios under AXA's internal model; no reinsurance collection issues have arisen in the review period, and all panel reinsurers hold at least A- ratings. The solvency filings explicitly state that no reinsurance arrangement has a material impact on the company's financial position, confirming that reinsurance is used for tail-risk protection rather than earnings reliance — a stance that keeps ceded premium leakage low while safeguarding the balance sheet from shock losses.
9. Solvency: AXA Tianping has maintained solvency ratios well above regulatory thresholds throughout 2020–2024 under China's C-ROSS II framework, with the Core Solvency Adequacy Ratio (Core CAR) ranging from 202% to 231% and the Comprehensive CAR from 202% to 240% against minimums of 50% and 100% respectively. Available capital of RMB 2.66 billion versus minimum required capital of RMB 1.11 billion at end-2024 provides a comfortable buffer of approximately RMB 1.55 billion; the divergence between core and comprehensive ratios since 2023 (core ~208%, comprehensive ~240%) reflects an inferred subordinated debt issuance that added Tier 2 capital and boosted the comprehensive measure. The NFRA's Integrated Risk Rating for AXA Tianping was "B" in both Q2 and Q3 2024 — denoting "good" risk management and full solvency compliance — with the company's on-site SARMRA assessment in 2022 scoring 72.82 out of 100. S&P revised the outlook to Positive in 2025, reflecting expectations of improving capitalization and profitability; if current trends persist, organic capital generation from returning profits will further strengthen ratios, reducing reliance on ancillary capital instruments.
10. Capital allocation: AXA Tianping has paid no dividends since the full AXA acquisition, as consecutive net losses left no distributable profits; all capital has been retained within the entity to fund the strategic pivot, consistent with Chinese regulatory restrictions on dividend payments during loss-making periods. The last major external capital action was AXA's 2014 RMB 2.0 billion injection at JV formation; post-2019 full ownership, the registered capital has remained at RMB 846 million with no new common equity injected, as solvency ratios have been managed through the 2023 subordinated debt issuance (estimated at a few hundred million RMB) rather than fresh equity. Capital within the business has been allocated toward IT investment, product development, and underwriting capacity for nationwide compulsory auto insurance — kept in safe, liquid assets rather than deployed in high-yield strategies — with OCI gains from bond market appreciation contributing RMB 176 million to equity in 2024 alone. Once AXA Tianping returns to profitability (projected by 2026), moderate dividends to AXA are plausible, though the parent's China growth ambitions suggest a significant portion of earnings will be reinvested; the overall capital management approach has consistently balanced regulatory prudence with growth funding, keeping solvency ratios comfortably above required levels throughout a challenging transition period.

AXA Tianping
AXA Tianping Property & Casualty Insurance Co., Ltd.
Corporate identity
Type	Subsidiary
Founded	2004
Headquarters	Shanghai, China
Regulator	National Financial Regulatory Administration (NFRA)
Ultimate parent	AXA S.A. (via AXA Versicherungen AG)
Major shareholders	AXA S.A. (100%, via AXA Versicherungen AG)
Key people	Zhu Shamiao (Chairwoman), Zuo Weihao / Kevin Chor (General Manager & CEO)
Number of employees	~2,600
Business & markets
Business segments	Motor Insurance, Health & Lifestyle, Commercial P&C
Main products & services	Mandatory auto liability (交强险), commercial auto insurance, short-term medical insurance, personal accident, critical illness, travel insurance, SME property and liability, new energy vehicle (NEV) insurance
Distribution	Direct (online platform, mobile app, telemarketing), digital partnerships (WeChat mini-programs, aggregators, automotive and travel affinity), agency and broker channels (via wholly-owned insurance sales subsidiary)
Market share rank	Largest 100% foreign-owned P&C insurer in China; #6 motor insurer in China (2017)
Key financials (2024)
Revenue	RMB 6.74 billion (Gross Written Premium)
Net income	RMB (66.2) million (net loss)
Total assets	~RMB 11.4 billion
Equity	~RMB 2.8 billion
External ratings	S&P: Outlook revised to Positive (2025) NFRA Integrated Risk Rating: B (2024 Q3)
Financials based on PRC GAAP (statutory accounts). All figures in CNY unless otherwise stated.

More details are in the following sections.

~*~

Corporate profile

🏢 Legal structure. AXA Tianping Property & Casualty Insurance Co., Ltd. (安盛天平财产保险有限公司) was originally established as Tianping Auto Insurance in 2004. It became a joint venture in 2014 when AXA acquired 50% (injecting RMB 2.0 billion), and was fully acquired by AXA in December 2019, making it the largest 100% foreign-owned P&C insurer in China. The AXA Group holds its interest via AXA Versicherungen AG, a wholly-owned subsidiary of AXA S.A. As a Wholly Foreign-Owned Enterprise (WFOE), AXA Tianping operates under China’s C-ROSS II solvency regime supervised by the National Financial Regulatory Administration (NFRA).

🏦 Capital foundation. AXA Tianping’s transition to full AXA ownership involved buying out domestic shareholders for RMB 4.6 billion. AXA’s 2019 buyout enabled full management control to accelerate strategy in China. The entity’s registered capital is RMB 846.216 million, unchanged post-acquisition, indicating no new equity issuance since the takeover. Instead, capital support has come via retained capital and AXA Group backing. Notably, no dividends have been paid out in recent years due to accumulated losses – all profits are retained or losses absorbed, and no such distributions were disclosed. Capital adequacy has also been bolstered by capital instruments; for example, in 2023 the company issued subordinated debt (reflected in a higher comprehensive vs. core solvency ratio) to strengthen its solvency margin.

📍 Operational footprint. The company maintains a national footprint with 25 provincial branch offices and 90+ sub-branches, covering around 20–25 provinces (over 85% of China’s GDP). Key branch locations include major regions such as Shanghai (head office), Beijing, Guangdong (plus Shenzhen), Zhejiang, Jiangsu, Sichuan, Hubei, Shandong, Chongqing, Tianjin, etc., as well as smaller regions like Guangxi, Yunnan, Shanxi, Anhui, Henan, Inner Mongolia, and city branches in Dalian, Ningbo, Qingdao, etc. This broad network originated from Tianping’s direct-sales model and gives AXA Tianping a pan-China presence. As of 2024, the company had on the order of 2,600 full-time employees (based on 2,661 staff participating in social insurance). This represents a streamlined workforce compared to ~6,000 employees a decade ago, reflecting efficiency efforts and outsourcing of non-core functions (a Tianping hallmark was “low-cost operations via non-core outsourcing” in earlier years).

👥 Leadership governance. The board and management have seen a localization of leadership post-AXA acquisition. Since September 2022, Chairwoman Zhu Shamiao (朱沙苗) leads the board, replacing a prior AXA-appointed executive; her appointment was approved by Shanghai CBIRC with document [2022]444. Zhu is a seasoned industry executive (formerly with Allianz China and AIA) and, as of 2024, also chairs AXA’s Shanghai reinsurance entity.

👔 Executive management. The General Manager (CEO) is Mr. Zuo Weihao (左伟豪, a.k.a. Kevin Chor), appointed December 2022 (approval [2022]736). Zuo has been tasked with driving strategic transformation and growth, leveraging experience from AXA Hong Kong in life & health roles. Prior to Zuo, the CEO role was held by Ms. Zhu Yaming (appointed mid-2021) and earlier by Mr. Choi Dongjun (Chairman in 2021). The current leadership has a strong mandate to pivot the company beyond its legacy motor focus into diversified personal lines, aligning with AXA’s global strategy. All senior appointments and directors have been duly approved by the regulator, and the company’s governance structure is sound and in full compliance with local requirements (the board is comprised of AXA representatives, and as a WFOE, there is no statutory board of supervisors).

~*~

Segment overview

🚗 Motor focus. Historically a mono-line motor insurer, AXA Tianping has been executing a strategic pivot to a more balanced product mix, expanding into Health & Lifestyle lines and selective Commercial P&C segments. Motor Insurance has been the core business since inception. As of 2017, motor policies contributed 91% of AXA Tianping’s gross premiums, reflecting its roots in auto insurance. The motor portfolio includes mandatory Auto Liability (交强险) and commercial auto insurance. Tianping was a market leader in direct motor insurance (6th largest motor insurer in China in 2017). Even today, motor remains the largest single segment, but its share of the portfolio has been steadily declining (to roughly 57% of total GWP by 2025, from over 90% five years prior).

🏥 Health expansion. AXA Tianping now positions Health insurance as a strategic growth engine, in line with AXA Group’s emphasis on being a “health partner”. The company sells short-term medical insurance, personal accident, and other lifestyle-related coverages. In 2018, these non-motor lines were minimal, but have since grown rapidly. By H1 2025, non-motor premiums (including health) accounted for ~43% of total premiums, a dramatic increase from ~9% in 2017. This category includes proprietary products and AXA’s global offerings localized for China (e.g. high-end medical plans, critical illness, travel and personal accident insurance). The pivot has been facilitated by AXA’s global health expertise and brand, allowing AXA Tianping to develop a “holistic wellbeing” value proposition in China. For example, the company emphasizes value-added health services, telemedicine access, and wellness programs as it transforms from a pure payer to a partner in customers’ health (adapting AXA’s “Payer-to-Partner” strategy to the local market).

🏭 Commercial niche. Commercial Lines (SME/Corporate) are traditionally a smaller portion of the portfolio, but AXA Tianping underwrites property and liability cover for small-and-medium enterprises and some corporate clients. Its license permits enterprise property insurance, cargo/marine, engineering, liability and credit insurance, etc. These have remained ancillary, but the company is selectively expanding in niches aligned with AXA’s global strengths (e.g. commercial motor fleets, liability covers for corporate clients, and emerging risks). For instance, AXA Tianping has started offering New Energy Vehicle (NEV) insurance and other specialized covers to tap into growth areas (supporting AXA’s green finance goals). Overall, commercial P&C still represents a modest share of premiums, but provides diversification and opportunities for reinsurance collaboration with AXA XL and others for complex risks.

💻 Direct channels. AXA Tianping employs a multi-channel distribution strategy, evolving from its direct-sales heritage to incorporate digital partnerships and intermediated channels. A legacy strength of Tianping, direct sales (online and telemarketing) remain a major channel. As of the late 2010s, 41% of the company’s motor premiums were sold through direct channels (online platforms and call centers) – one of the highest direct ratios in the market. The company continues to leverage its online platform and mobile app for direct sales of motor and health products, targeting the digital-savvy consumer segment. Telemarketing call centers and its website were key in Tianping’s early growth, and these direct capabilities have since been enhanced with AXA’s investment in digital tools. Direct distribution has helped control acquisition costs and will remain critical for simple products (auto, travel, simple health).

🔗 Digital alliances. AXA Tianping has formed tie-ups with Chinese digital ecosystems to extend reach. This includes presence on insurance aggregators and online insurance marketplaces, as well as strategic partnerships. Notably, in 2024 AXA Tianping led an initiative for AXA Group to sign an MOU with PICC Group, China’s largest P&C insurer, to collaborate on distribution and services. This partnership aims to improve geographic service networks (PICC’s local offices can facilitate AXA claims services, for example) and mutual reinsurance support. The company is also integrated into platforms like WeChat for quote and purchase of simple policies, and partners with automotive companies and online travel agencies to offer embedded insurance (such as auto insurance bundled with new car sales or travel cover on booking sites). These digital and affinity partnerships are geared to capture younger customers and niche markets at low cost.

🤝 Agency network. While historically less reliant on traditional agents, AXA Tianping does utilize agency channels, including both independent insurance brokers and a captive agency force. The company owns a wholly-owned insurance sales subsidiary (安盛天平保险销售有限公司) to handle certain agency operations. Agents and brokers are particularly important for commercial lines and more complex products (and also to reach customers in regions where direct digital presence is weaker). AXA Tianping’s branch network supports a local agent network in each province.

⚖️ Omnichannel balance. The agency channel contributes a smaller portion of personal motor premiums compared to peers, owing to Tianping’s direct model. Management has indicated a focus on cost-efficient channels, meaning they are selective with broker business to avoid high commissions and focus on agents where they add value (e.g., selling packaged health plans to SME employers, etc.). The distribution mix is thus becoming balanced: direct/digital channels drive personal retail lines, while agency/broker channels supplement growth in health and commercial lines. Overall, AXA Tianping’s distribution strategy is omnichannel, with a continuing emphasis on digitalization and direct sales to support its pivot to health and lifestyle products, in line with AXA’s global approach of leveraging technology and partnerships to reach customers.

~*~

Segment performance

📊 Premium dynamics. The company’s Gross Written Premium (GWP) has remained roughly stable to modestly growing in recent years, but with a significant internal shift from motor to non-motor lines. Total GWP was RMB 7.418 billion in 2020, dropped to 5.944 billion in 2021, then recovered to 6.074 billion in 2022, and grew to 6.535 billion in 2023 and 6.741 billion in 2024. The sharp dip in 2021 reflects the Comprehensive Auto Insurance Reform impact and pandemic effects, after which growth resumed. Within the premium mix, Motor insurance now constitutes around 60% of GWP (2024), down from ~74% of the market in 2017 and over 90% of AXA Tianping’s own portfolio pre-pivot.

📈 Growth outlook. Conversely, Non-Motor lines (health, accident, property, liability) have grown to ~40% of GWP. S&P reports that non-motor business was ~43% of premiums in H1 2025, and expects 7–10% annual GWP growth through 2027 led by non-motor lines. This indicates AXA Tianping’s strategy is yielding a more balanced book: the health/lifestyle segment has seen double-digit growth, offsetting flat motor premiums. Indeed, motor premium growth is expected to stay low (mid-single digits) due to selective underwriting and market saturation, while health and other lines drive overall top-line expansion.

📉 Underwriting results. AXA Tianping has struggled with underwriting losses in recent years, but these are narrowing. The combined ratio (loss ratio + expense ratio) has averaged about 109% over the past five years, indicating persistent underwriting losses. However, performance is improving: the combined ratio was ~106% for full-year 2024, down from the ~109% average, and S&P projects it will improve further to about 100–105% over the next two years. Key drivers of this trend are tighter risk selection (pruning unprofitable motor business), lower acquisition costs (growing direct/digital sales), and expense control.

🚗 Regulatory impact. The 2020 Auto Insurance Reform had a profound impact on motor underwriting. Effective September 2020, regulators increased coverage limits (e.g. compulsory liability limit from ¥122k to ¥200k) and slashed premium rates and commissions – the commercial auto insurance expense ratio cap was cut from 35% to 25%, with an expected claims ratio increase from 65% to 75%. This led to an average 20% drop in auto premium per vehicle nationwide. For AXA Tianping, whose book was heavily motor, the reform caused a sharp premium decline in late 2020 into 2021 and initial deterioration in loss ratio. Indeed, AXA Tianping’s motor GWP fell ~20% and the combined ratio spiked above 110% in 2021, contributing to a larger net loss that year.

🛠️ Strategic adjustment. Over 2021–2022, the company adjusted: it reduced costs (including agent commissions and operating expenses) and repriced high-risk segments. By 2023, motor underwriting results had stabilized, albeit still around break-even levels (the motor loss ratio remains high ~70+%, but expense ratio improvements have offset this). The reform’s positive effect is that customers got cheaper premiums (average motor premium in China fell by ~¥700, or 20%) and richer coverage, which in the long run could improve customer retention. However, for insurers it compressed margins. AXA Tianping responded by shrinking unprofitable motor segments and focusing on retention of lower-risk customers, leveraging telematics and pricing sophistication from AXA.

📉 Loss containment. Motor claims frequency has trended favorably (fewer accidents during COVID lockdowns in 2020, and improved car safety features), but severity has risen (higher repair costs, larger liability limits). These dynamics kept motor combined ratios around or just above 100% in 2022–2024. The company expects only modest motor growth going forward and is not chasing volume at the expense of underwriting profit.

💊 Health profitability. The non-motor lines, especially short-term health insurance, have been the growth engine with relatively better margins. AXA Tianping’s health loss ratio has been manageable, though medical claims inflation (high medical cost trend in China ~10%+) is a concern. The company leverages AXA’s product expertise to design health policies with sustainable pricing and uses reinsurance to mitigate volatility. In 2022–2024, health insurance growth was very strong (premium growth well over 30% annually, albeit from a low base).

🚑 Margin management. The loss ratio on health has been kept in check through careful underwriting – for example, focusing on group business and higher-end individual plans, and implementing claims controls (preferred provider networks, etc.). However, as this book grows, medical inflation and Covid-related claims spikes can pressure margins. The expense ratio on new health business is also high initially due to distribution commissions (when using brokers or partner channels). Despite these challenges, the non-motor segment has improved the overall combined ratio: its profitability is slightly better than motor’s. Expense-wise, health products often carry lower acquisition cost ratios than motor (since some are sold direct or via cross-sell to existing auto clients). The net effect is that the diversification into health/lifestyle is gradually lowering the company’s overall combined ratio by offsetting the slim margins of auto.

📉 Expense control. AXA Tianping’s expense ratio (management expenses + acquisition costs) has been a focus for improvement. As a former direct insurer, it already had a lean cost structure relative to peers that rely on agents. Still, the pivot to new lines required investments (IT systems for health insurance, new product development, etc.), which kept the expense ratio elevated in the short term. The company has since implemented cost control measures: integrating operations with AXA’s regional platforms, outsourcing certain back-office tasks, and optimizing branch overhead.

💰 Cost efficiency. By 2024, these efforts helped reduce the management expense ratio. Meanwhile, acquisition cost (commission) ratio also declined post-2020 thanks to the regulatory cap in motor and the shift to direct channels. S&P specifically noted “continued expense management” as a factor improving underwriting results. Overall, the company’s total expense ratio has trended down, contributing to the narrowing of underwriting losses. For example, operating expenses dropped from RMB ~6.21 billion in 2021 to RMB ~5.88 billion in 2024, even as premium volume grew – indicating improved efficiency. This bodes well for reaching an underwriting break-even: combined ratio approaching 100% in the near term.

🏁 Performance summary. In summary, AXA Tianping’s segment performance reflects a company in transition: motor insurance remains a large but low-margin line facing regulatory-induced pricing pressure, while health and other non-motor lines are rapidly growing and expected to deliver better margins long-term. The underwriting loss is shrinking each year (net loss reduced from ¥275 million in 2021 to ¥66 million in 2024), reinforcing that the pivot is yielding improvements. Management’s target is to swing to net underwriting profit by 2026, which appears attainable if current trends (premium growth + combined ratio decline) continue.

~*~

Strategy priorities

🎯 Strategic goals. AXA Tianping’s strategic priorities center on diversification, customer-centric innovation, and digital transformation, aligning with AXA Group’s global vision but tailored to the Chinese market. Key thrusts include reducing over-reliance on auto insurance as priority #1. The company’s strategy explicitly aims to lower the motor concentration by expanding in health, accident, and commercial P&C lines. This is both a risk management move and a growth play, given motor insurance in China is low-growth and highly competitive post-reform.

🔄 Diversification plan. Management has laid out plans to have at least half of its business from non-motor lines in the coming years. The successful growth of health premiums to 43% of the book by mid-2025 shows progress. AXA Tianping is introducing new products such as critical illness policies, high-end medical insurance, and lifestyle-focused coverages (e.g. insurance for pets, travel, and personal cyber protection) to capture consumer demand beyond auto. It is also targeting SME commercial lines selectively – for instance, offering packaged solutions (property, liability, group health) for small businesses. This diversification not only opens new revenue streams but also balances the risk portfolio (since motor risk is heavily correlated with regulatory changes and market price wars). Ultimately, the goal is a more resilient business mix where no single segment (like motor) dominates.

🏥 Health partnership. In lockstep with AXA’s global Health strategy, AXA Tianping is pivoting from a pure indemnity insurer to a partner in customers’ healthcare and lifestyle. This entails offering value-added services on top of insurance coverage. For example, the company has been implementing AXA’s “Payer-to-Partner” model by integrating telemedicine, wellness coaching, chronic disease management programs, and mental health support into its health insurance products. AXA Tianping leverages AXA’s global health tech investments (such as the Emma by AXA app and telehealth platforms) adapted for China. The aim is to differentiate its health offerings in a market where many insurers compete on price alone.

🧘 Wellbeing ecosystem. As noted by AXA Asia executives, the strategy is to “champion healthcare and mobility solutions” in China by combining AXA Tianping’s local infrastructure with AXA’s global expertise in health and digital services. Concretely, this means AXA Tianping is developing a holistic wellbeing offering – for instance, high-end medical insurance customers get access to international medical networks and second medical opinion services. Motor insurance clients are offered value-adds like roadside assistance and driver safety apps; and corporate clients receive risk management and wellness seminars for employees. By becoming a partner, AXA Tianping aims to improve customer loyalty and tap into the fast-growing health market (which has been growing ~39% p.a. in China).

💻 Digital investments. Embracing digital technology is a cornerstone of AXA Tianping’s strategy to enable high-frequency, customer-friendly services. The company has invested significantly in its IT infrastructure to support digital sales and claims. One focus is building a robust online claims system for motor and health – enabling e-claims submission, fast adjudication, and AI-driven fraud detection. For health insurance, where claims can be high-volume (outpatient visits, etc.), AXA Tianping upgraded systems to process claims with minimal paperwork and even offer cashless settlements at partner hospitals (direct billing). The insurer is also utilizing data analytics and AI to improve underwriting and pricing (for example, using telematics data for motor insurance pricing and health data for customized premiums).

📱 Customer experience. Another aspect is partnering with fintech and InsurTech players: AXA Tianping was one of the early adopters of online distribution in China and continues to experiment with new digital channels – e.g., mini-programs on WeChat for quick policy issuance, and integration with e-commerce apps. The customer experience is being enhanced via mobile apps that allow policy management, instant quotations, and renewals. Internally, digital transformation also means streamlining operations – migrating to cloud-based core systems (in line with C-ROSS II data requirements) and automating back-office processes. These efforts support the strategy by lowering operating costs (improving the expense ratio) and enabling scalable growth in high-volume lines like health.

🚗 Mobility innovation. Given its motor background, AXA Tianping is re-framing its auto insurance approach toward “mobility” solutions. This includes usage-based insurance (UBI) pilots, coverage for new mobility modes (ride-sharing drivers, electric vehicles, etc.), and value-added services for drivers. In 2024, the company highlighted new energy vehicle insurance as a growth area that also aligns with green initiatives. Partnering with automakers and leveraging AXA’s experience in telematics in Europe, AXA Tianping plans to offer tailor-made motor products (for example, insurance that factors in EV battery risk or telematics-based safe driving discounts). The broader strategy is to transform from just compensating car accidents to helping customers avoid accidents and manage their mobility needs (through driver coaching, accident prevention alerts, etc.).

🌍 Group synergies. AXA Tianping’s strategy heavily relies on support from the parent group. AXA provides technical expertise (in pricing, product design, risk management) and reinsurance support (particularly for large risks and catastrophes). The local entity’s strategic plan explicitly notes leveraging “AXA’s global Health and P&C expertise” and brand to selectively target preferred customer segments. For example, AXA Tianping has adopted global best practices in risk modeling (to satisfy C-ROSS II capital rules) and uses AXA’s group procurement to reduce costs (e.g., negotiating IT contracts at group level). The parent has also shown commitment through capital oversight – ensuring AXA Tianping maintains a solid solvency margin to pursue growth.

📈 Future vision. In short, AXA Tianping’s strategy is not standalone; it is an integral part of AXA’s “Growth Markets” strategy, with China seen as a key engine. The full ownership allows AXA to implement its vision (health focus, digital, and sustainability) directly via Tianping. Indeed, the acquisition press release underscored that AXA Tianping is a platform to “capture the significant growth potential of P&C and health in China”, and the strategy since 2019 has followed through on that intent. In summary, AXA Tianping’s strategy priorities can be summed up as diversify, digitalize, and differentiate. By reducing motor dependence, becoming a health partner to customers, and harnessing technology, the company is steering towards sustainable profitability and a position as AXA’s flagship general insurer in China’s evolving market.

~*~

Income statement

💴 Financial overview. The financial performance of AXA Tianping over the past 5 years reflects the challenging motor market and the costs of strategic transition, but also shows a trend of improvement. The figures below are based on PRC GAAP from the company’s statutory reports (consolidated basis). All amounts are in CNY millions.

Metric (CNY millions)	FY2020	FY2021	FY2022	FY2023	FY2024	Notes / Drivers
Gross Written Premium (GWP) (“Insurance business income”)	7,418.0	5,943.7	6,074.5	6,535.0	6,740.6	Sharp drop in 2021 due to auto rate cuts; growth resumed 2022–24 led by health. GWP includes direct + inward reinsurance premiums.
Net Premiums Earned (Net Premium Revenue)	6,962.0	5,498.7	5,490.5	5,552.4	5,537.5	Earned premium follows GWP trend with a lag. 2021 earned premium down ~21%. Flat in 2022–24 due to unearned premium reserve movements.
Investment Income	285.6	283.4	264.4	283.2	237.5	Largely interest and dividend income. Stable ~¥280m through 2021, dipped in 2022 (conservative portfolio). 2023 rebounded with one-off gain (sold subsidiary), 2024 lower due to market yields.
Operating Expenses (Total claims, commissions, mgmt expenses)	7,539.7	6,215.4	6,038.7	6,004.4	5,881.8	Total expenses have decreased despite premium growth – reflects cost cutting and lower acquisition costs. 2020 was high pre-reform. 2021–22 saw reduced commissions (regulatory cap) and efficiency gains by 2024.
Net Profit (Loss)	(192.7)	(275.8)	(174.7)	(98.6)	(66.2)	All years net losses. Loss peaked in 2021 (post-reform shock), then narrowed each year. 2024 loss ~¥66m, on track to breakeven by 2025–26. No dividends paid during loss years.

📉 Loss trajectory. AXA Tianping has been in a loss-making position throughout 2020–2024, but the trajectory is clearly improving. Net loss shrank from ¥275.8 m in 2021 to ¥66.2 m in 2024, while the combined ratio gradually declined (from ~110%+ in 2020–21 to ~106% in 2024), indicating the company is nearing the inflection point of profitability. Top-line (GWP) volatility in this period was driven by regulatory changes: the 2020 auto reform caused a steep ~20% revenue decline into 2021, after which growth resumed as the company diversified into health and regained motor volume. By 2024, GWP (¥6.74 b) slightly exceeded the pre-reform 2019 level (≈¥6.5 b), indicating the pivot strategy has effectively rebuilt the premium base with a healthier mix. Net earned premiums stayed around ¥5.5–5.6 b in 2021–2024, reflecting slow growth and the impact of increased unearned premium reserves from new health business (health policies often have premiums earned over time, dampening immediate revenue recognition).

💰 Investment returns. Investment income has provided a stable secondary revenue, averaging ~¥260–280 m, which helped offset underwriting losses. The investment portfolio is conservative with a high allocation to bonds and cash, yielding around 4–5% annually as guided by the CIO. A slight dip in 2022’s investment result was due to market interest rate swings and a prudent shift to higher credit quality, shorter duration bonds. 2023’s investment line included a one-off gain of ~¥50 m from the sale of a subsidiary (AXA Tianping Insurance Sales Co.), boosting income. By 2024, lower interest rates and realized losses on some assets led to reduced investment income (¥237.5 m).

📉 Expense management. Operating expenses have trended downward in absolute terms, which is notable given some premium growth – a sign of improved efficiency. Claims incurred (the largest component of expenses) were high in 2020–21 due to the premium rate cuts (claims didn’t drop proportionally to premium). However, by 2022–24, claim costs were better controlled and commission expenses fell (post-reform commission limits). Management expense discipline also kicked in: the company’s cost-cutting measures yielded savings, evident in the drop of total expenses from ¥6.21 b in 2021 to ¥5.88 b in 2024. The underwriting result (premiums minus claims and expenses) is still negative but much smaller: the underwriting loss was ~¥389 m in 2021, improving to ~¥238 m in 2022, and ~¥93 m in 2024.

📈 Turnaround progress. In summary, the P&L shows that AXA Tianping’s turnaround is in progress. The company has been effectively using investment income and cost containment to cover underwriting shortfalls. With continued top-line growth and combined ratio improvement, AXA Tianping is expected to turn the corner to net profit by 2026. (Indeed, S&P forecasts a return to profit by 2026 as expense and loss ratios improve to just at or below 100%.) All financial figures above are under PRC GAAP for the local entity. It should be noted that AXA Group’s IFRS17 accounts may reflect different figures (e.g. “insurance revenue” instead of GWP), but for consistency this analysis sticks to local statutory numbers.

~*~

Balance sheet

⚖️ Asset composition. AXA Tianping’s balance sheet remained solid through 2020–2024, underpinned by shareholder support and a conservative investment portfolio. As of end-2024, total assets were approximately CNY 11.4 billion (unchanged in the ¥10–12 b range over 2020–2024). The asset mix is highly liquid and low-risk, reflecting prudent investment strategy. Cash and bank deposits make up a large portion, as the company kept liquidity high post-2020 (partly in response to the motor reform uncertainty). Fixed-income investments (primarily government and high-grade corporate bonds) constitute the bulk of invested assets.

🛡️ Investment policy. According to management, AXA Tianping maintained a high liquidity asset ratio and reduced its investment yield target to ~4.5% to control credit and market risk. By end-2023, for example, about 48% of the portfolio was in government bonds and policy bank bonds, 30% in high-grade corporate bonds, and only a small single-digit percentage in equities. The equity holdings are minimal, limited to strategic or legacy positions, due to the company’s aversion to market volatility (realized equity gains/losses were negligible in this period). Real estate exposure is also minimal (no direct property holdings on balance sheet). The remainder of assets includes premium receivables (which are kept in check by tight credit control on agents), reinsurance recoverables (small given low cession rates), and deferred tax assets (built up from accumulated tax losses – these assets have grown but are partially offset by valuation allowances given recurring losses). Overall, the asset side is very conservative, prioritizing capital preservation over yield, in line with AXA Group’s risk management standards in emerging markets.

📉 Reserve liabilities. The largest liabilities are insurance contract liabilities, primarily unearned premium reserve (UPR) and claim reserves. At end-2024, net UPR was around ¥1.91 b and net outstanding claims reserve about ¥2.07 b (for reference, 2023 net claim reserve was ¥2.07 b after IFRS/GAAP adjustments). Motor insurance reserves still dominate (since motor claims can be long-tail for bodily injury). Post reform, average motor premium fell but coverage expanded, which means reserves per policy increased (higher potential losses). The loss reserves have been consistently booked with a cautious approach – an external actuarial opinion is provided annually (the 2024 actuarial report presumably gave a clean bill on reserve adequacy).

⚕️ Health reserves. Health insurance reserves (for short-term health) are growing as that book expands; however, since most health policies are short-duration, their claim reserves turn over quickly. There is also a growing unearned premium reserve for health and accident business due to rapid premium growth, which partly explains why earned premium lags GWP (unearned portion carried as liability). The reserves include a risk margin under C-ROSS II framework, which AXA Tianping sets using both regulatory and AXA Group methodologies (e.g., a risk margin equal to 3% of unearned motor premium, etc., as per internal model). Insurance payables (commissions payable, reinsurance payables) are other liability items but relatively small.

🧾 Other liabilities. AXA Tianping has no significant debt aside from a recent subordinated bond issuance. In 2023, the company likely issued a capital supplementary bond (subordinated debt) to strengthen capital – though the exact amount is not publicly disclosed, it can be inferred from the jump in comprehensive solvency ratio (the ~$50 m Tier 2 capital would appear as a liability). Aside from that, liabilities include insurance protection fund payable (the mandatory industry guarantee fund accrual) and normal accruals (salaries, taxes). There are no complex liabilities like derivatives or borrowings on the balance sheet.

💰 Equity structure. As of end-2024, total equity (net assets) stood at ~CNY 2.8 billion. This is down from ~¥3.2 billion in 2019, due to cumulative losses since then. The registered capital remains ¥846 million fully paid-in. Capital was actually reduced by ¥1.5 b in 2019 as part of the share buyback (to facilitate AXA’s acquisition), but that reduction was effectively replaced by AXA’s direct ownership and capital support. The capital surplus and surplus reserves are modest. Retained earnings are negative given consecutive losses (an accumulated deficit of roughly ¥0.9 b by 2024).

📈 Equity support. However, this is offset by other components of equity: notably, other comprehensive income (OCI) from available-for-sale investments. In 2024, rising bond market values led to a significant OCI gain of ¥176 m, directly boosting equity (this OCI swing actually made total comprehensive income positive in 2024 despite the net loss). AXA Tianping’s equity has also been supported by parental injections when needed: while no new common equity was injected post-2019, the parent did ensure the company’s capital position remained solid (through the aforementioned sub-debt and by foregoing dividends). The solvency section (§9) shows the actual capital vs. regulatory required capital, highlighting a healthy capital buffer in equity terms.

🏗️ Financial stability. In summary, AXA Tianping’s balance sheet is conservative and adequately capitalized. Assets are largely liquid, high-quality investments that match the liability profile. The insurer has maintained more than sufficient reserves and has not engaged in aggressive investment strategies. Equity has been gradually eroded by operating losses, but the parent’s commitment to the China business means capital support is available. In fact, AXA Tianping’s capital base was about USD 400 million (~RMB 2.66 b) at end-2024, and S&P assesses the capital position as “satisfactory” with continued AXA Group backing. There is no concern about going-concern given AXA’s backing and the improving financial trend. The balance sheet strength underpins the company’s ability to underwrite new business and pursue its strategic pivot without breaching regulatory solvency requirements.

~*~

Claims & Reserving

🚗 Motor claims trends. AXA Tianping’s claims portfolio is dominated by high-frequency motor claims and an increasing volume of health claims. Following the 2020 auto reform and pandemic, motor claims frequency initially decreased (fewer accidents during COVID lockdowns and as driving patterns shifted). However, with economic activity largely normalized by 2021–2022, claim counts returned to typical levels. The reform’s impact was more on severity: higher third-party liability limits led to larger average claim payouts for serious accidents. For instance, the compulsory auto liability limit increased to ¥200k (from ¥122k), and many drivers increased their voluntary third-party liability coverage to ¥1 million or more, which means AXA Tianping is exposed to higher potential losses per claim.

📉 Claims management. Industry data showed average motor third-party claim size rose after reform, though the frequency of very large claims remains low. AXA Tianping has managed these trends by adjusting its reinsurance protection and focusing on safer driver segments. Claims inflation for motor (parts and labor costs) has been moderate, around 3-5% annually, but supply chain issues in 2021 caused a spike in certain repair costs. The company’s direct repair network and agreements with garages have helped control repair costs. Overall, post-reform motor loss ratios spiked above 70% in 2021 (industry-wide) but have since improved to mid-60%s by 2023 as premium rates stabilized and claims frequency remained in check. AXA Tianping’s own motor loss ratio is estimated around 65-70% in 2024, reflecting these industry trends (not publicly broken out, but implied by segment reporting).

⚕️ Health claims. As the health insurance book expands, AXA Tianping is increasingly exposed to medical claims inflation, which in China can be high (double-digit annual increases in medical costs). Short-term health insurance typically has annual repricing, so the company can adjust premiums to track medical inflation, but there is a lag effect. In 2022–2024, health claims have grown proportionally with business volume. The claims ratio on health has been roughly stable – thanks in part to careful product design (e.g., deductibles and copays on medical plans to mitigate small claims). The company has seen an uptick in health claims frequency, especially out-patient and minor claims, which it addresses through managed care techniques (for example, offering network arrangements that cap costs). COVID-19 had some impact: in late 2022 and early 2023, the end of zero-COVID led to a surge in medical claims (for those plans covering COVID). However, these were short-term spikes and manageable within reserves; AXA Tianping monitors medical inflation and utilization closely.

🌪️ Catastrophe risk. Natural catastrophe risk in the AXA Tianping portfolio is relatively limited given the focus on personal lines. The main cat risks are floods, typhoons, and hail affecting auto insurance. For example, in summer 2021, severe flooding in Henan province led to thousands of vehicles being inundated – industry losses were significant. AXA Tianping, with a presence in Henan, incurred claims from flooded cars (these are covered under auto physical damage). However, the company’s national spread diversifies such events, and it also utilizes catastrophe reinsurance cover (likely through AXA Global Re or China Re) to cap net losses from any single event. Typhoons in coastal provinces (Guangdong, Zhejiang, etc.) similarly can cause auto and property claims (fallen trees on cars, etc.), but again these are managed via reinsurance. The commercial property exposure that AXA Tianping has is modest and often protected by reinsurance as well. So far, no single nat cat event in 2020–2024 materially impacted the financials (none are noted as “major losses” in reports). Cat losses contributed to claims volatility but were within the company’s risk appetite and absorbed by reinsurance where needed.

📝 Motor reserving. AXA Tianping employs a prudent approach to claims reserving, in line with regulatory requirements and AXA Group standards. Motor claims reserves consist of case reserves for reported claims plus IBNR (incurred but not reported) reserves for late-reported claims. The company uses historical development patterns to estimate IBNR; given motor is short-tailed (most claims reported quickly), the reserving risk is moderate. The 2020 reform did introduce uncertainty in liability claims – to address this, AXA Tianping strengthened its bodily injury reserving assumptions initially (since claims limits increased, they assumed higher average payouts). Over 2021–2022, as actual experience emerged, reserves were adjusted accordingly. As of end-2024, the outstanding claims reserve for motor is believed to be adequate with a slight margin. The actuarial team conducts quarterly reserve adequacy tests; regulators require that reserves be sufficient at a high confidence level. AXA Tianping’s 2022 annual report explicitly states an actuarial certification that reserves are adequate and no deficiencies were found.

📊 Health reserving. For short-term health and accident, reserves include UPR (for the unexpired risk period) and claim reserves for reported claims. Short-term health products, especially those sold in Q4, generate a sizable UPR carried into the next year. AXA Tianping evaluates whether UPR is sufficient to cover expected claims via a Premium Deficiency Reserve (PDR) test. So far, there is no indication that a PDR was needed – loss ratios on unearned portions are within allowable range, meaning the UPR is enough. For claims reserves on health, because these policies can have a reporting lag (e.g., a hospitalization in December might be claimed in January), the company sets IBNR using chain-ladder methods on loss triangles. With the business expanding, there is some uncertainty, but the reserves are set with conservative margins for IBNR.

⚖️ Long-tail liabilities. AXA Tianping has minimal long-tail business (like liability or credit insurance). One exception is the compulsory auto liability, which can have long-tail injury claims. For such long-tail exposures, the insurer uses industry tables and AXA Group expertise for reserving. There is no indication of reserve shortfall; in fact, the solvency reports did not flag any issues with reserve adequacy (no regulatory adverse findings). The company did not have to significantly boost reserves beyond normal development, which suggests prior year reserves have developed slightly redundantly or in line with expectations. The speed of claim settlement is improving through digital processes, which also feeds into reserving. Faster settlements mean less reserve uncertainty. AXA Tianping’s average motor claim closure time has shortened, reducing the proportion of outstanding claims at period-end.

✅ Clean position. In summary, claims trends have been challenging (motor down pricing, health up usage) but manageable. The reserving for those claims appears adequate and conservative. The company has not had reserve shocks; if anything, reserve releases from prior years have occasionally benefited earnings (though minimal). The solvency filings explicitly state that as of year-end, the insurer had no material outstanding issues in reserves and no off-balance-sheet commitments or contingent liabilities related to claims. This indicates a clean reserving position. Stakeholders (including regulators and auditors) view AXA Tianping’s reserving and claims management as satisfactory, and the insurer continues to refine these practices with AXA’s global actuarial support.

~*~

Reinsurance

☂️ Reinsurance structure. AXA Tianping utilizes reinsurance primarily to protect its capital from large losses and to manage accumulations (particularly in motor catastrophic events and fledgling commercial lines). However, as a predominantly retail insurer, its overall ceding ratio is relatively low – typically around 10-15% of premiums are ceded. The reinsurance program is designed with a combination of internal group reinsurance and local market reinsurers. For high-sum insured policies (mostly in commercial lines), AXA Tianping uses surplus treaties to cede portions exceeding its net retention. Given the company’s modest commercial portfolio, these treaties are not heavily utilized, but they provide capacity for any larger industrial risks underwritten. In personal lines, quota share reinsurance has been used selectively – for example, in some years AXA Tianping ceded a small quota share of its motor book to AXA Group’s internal reinsurer to diversify risk. This helps reduce the net motor exposure and volatility.

🛡️ Loss protection. The ceded premium line in financials (around ¥0.7–1.0 b per year) corresponds to these arrangements. The overall retention is high (~87-90% retention), reflecting that most retail risk is kept net. A critical part of the program is excess-of-loss reinsurance for catastrophic events and large single losses. AXA Tianping purchases catastrophe XL cover that aggregates motor and property losses from natural perils. For instance, a catastrophe XOL treaty might cover aggregate losses above a certain threshold (say ¥50 m) up to a higher limit for events like a major flood or earthquake affecting many insured cars. The lead reinsurer for cat covers is often China Re P&C, given regulatory preferences for using domestic reinsurers, but AXA likely also involves AXA XL (the group’s commercial reinsurance arm) or other international reinsurers for capacity. Additionally, the company likely has a motor per risk XOL to cap any single large third-party liability claim (for example, losses above ¥5 m perhaps ceded to reinsurers). These XOL covers ensure that even a very severe car accident or court award would not hit the net account beyond the retention.

🏢 Group reinsurance. As part of AXA Group, AXA Tianping accesses internal reinsurance. AXA has a global reinsurance entity (AXA Global Re) that often provides group covers. In the case of AXA Tianping, certain treaties may be fronted to AXA: for example, an internal quota share treaty or a stop-loss cover to limit annual underwriting losses. However, the disclosed reports indicate no unusually large related-party reinsurance transactions – the annual disclosure for 2024 notes that all major related-party transactions were properly reported, and no funds-utilization related-party deals occurred. A previous related-party reinsurance noted was a health reinsurance deal with AXA’s PPP healthcare unit in 2019, but such deals are routine and not material to solvency. The company’s reinsurance counterparty selection follows both CBIRC’s approved list and AXA Group’s internal credit criteria, ensuring high credit quality. All reinsurers on its panel have at least A- ratings and are vetted by AXA’s central risk team.

💰 Retention strategy. AXA Tianping’s retention levels reflect its capital strength and risk appetite. For mass retail business (motor, health), it retains the bulk of risk, which is appropriate given the law of large numbers and its sizable capital buffer. For example, it retains essentially 100% of each standard motor policy (except in catastrophe scenarios or very large claims as per XOL cover). For commercial risks, retention is more limited – e.g., a single property risk might have a net retention of a few million RMB, with the rest ceded via surplus treaty. The company has no exposure to mega industrial risks, so it hasn’t required facultative reinsurance on a regular basis. If it were to underwrite something unusual, it would arrange facultative cover likely through AXA XL. The solvency report explicitly stated that no reinsurance arrangement has a major impact on the company’s financial position, indicating that the reinsurance usage is for protection rather than earnings reliance.

✅ Risk management. The balance of recoverables is low relative to premiums, which means counterparty risk is modest. AXA Tianping monitors reinsurer credit risk carefully; all reinsurance contracts are logged in the system and approved by senior management to ensure collectability. In recent years, there have been no issues in collecting reinsurance claims. The integrated risk management report notes that reinsurance counterparties are all in compliance and that the company did not identify material credit risk concerns with reinsurers. In summary, AXA Tianping’s reinsurance strategy is protective and conservative. It relies on internal AXA reinsurance for strategic support (ensuring the China entity doesn’t bear outsized risks alone) and on local reinsurers like China Re for regulatory alignment and capacity. The retention is optimized to keep everyday claims net (avoiding unnecessary ceded premium leakage) while mitigating tail risks. This strategy has been effective: even major catastrophe losses or large claims in the past five years did not materially impair financial results, thanks to reinsurance. Moreover, AXA Group’s oversight ensures the reinsurance program is robust – for example, group reviews help structure adequate cat cover for 1-in-200 year events as per internal model. Thus, AXA Tianping benefits from both worlds: global expertise and local support in its reinsurance program.

~*~

Solvency

🛡️ Capital metrics. AXA Tianping is subject to China’s Risk-Oriented Solvency System (C-ROSS) Phase II, which sets capital requirements and risk ratings for insurers. The company has consistently maintained solvency ratios well above regulatory minima, underscoring a strong capital position. Key solvency metrics for the last five year-ends are as follows:

Metric	FY2020	FY2021	FY2022	FY2023	FY2024	Regulatory Min.
Core Solvency Ratio (Core CAR)	231.4%	223.0%	201.9%	204.7%	207.5%	> 50% (Core Tier 1)
Comprehensive Solvency Ratio	236.1%	228.1%	201.9%	237.8%	239.7%	> 100% (Core+Tier 2)
Actual Capital (¥ million)	2,789	2,480	2,208	2,471	2,663	–
Minimum Capital (¥ million)	1,181	1,087	1,093	1,039	1,111	–
Latest NFRA Risk Rating	n/a	A (est.)	A (est.)	B (2024 Q2)	B (2024 Q3)	(Class A: best, D: worst)

📊 Adequacy ratios. Throughout 2020–2024, AXA Tianping’s solvency ratios remained well above the regulatory thresholds (50% core, 100% comprehensive). The Core Solvency Adequacy Ratio (Core SCR) indicates the ratio of Tier 1 capital to minimum required capital, while Comprehensive includes eligible Tier 2 capital. In 2020–2022, the core and comprehensive ratios were effectively the same (~202–236%), implying the company had little or no Tier 2 capital in use. By 2023–2024, a gap emerged (Core ~205%, Comprehensive ~238%), indicating the inclusion of some Tier 2 capital (e.g., a subordinated debt issuance) which boosted the comprehensive ratio above the core. This suggests AXA Tianping added roughly ¥300–350 m of ancillary capital in 2023 to strengthen solvency. Even so, Tier 1 capital alone is about double the regulatory minimum (207% core CAR in 2024).

💰 Capital buffer. The actual capital (available capital) was ¥2.66 b vs requirement of ¥1.11 b at end-2024 – a comfortable buffer. Minimum capital (required capital) has fluctuated slightly with business risk profile: it peaked around ¥1.18 b in 2020, dropped in 2021–2023 as premium volume and risk reduced, and edged up to ¥1.11 b in 2024 as business grew again. The solvency ratios dipped in 2022 (to ~202%) mainly due to net losses reducing capital and Phase II calibration changes, but rebounded in 2023 after capital management actions. Overall, AXA Tianping’s solvency ratios are strong and in line with well-capitalized peers, reflecting prudent capital management by the parent.

📉 Risk rating. Under C-ROSS II, insurers are also subject to an Integrated Risk Rating each quarter (formerly called the Solvency Aligned Risk Management Requirement and Assessment, SARMRA). The NFRA assigns grades: Class A (excellent), B (good), C (concern), D (high risk). AXA Tianping’s recent assessments have been in the B category. Specifically, in 2024 Q2 and Q3, its comprehensive risk rating was “BB” (which the context implies a Category B rating). This meets regulatory standards for solvency (A and B are considered solvency-compliant).

🛡️ Risk management. The B rating suggests some room to improve (perhaps due to just breaking even profitability and moderate size), but no major regulatory concerns. In earlier years, the company likely had A ratings when solvency ratios were very high. However, the transition to Phase II and continued losses might have led to a downgrade to B. The company “highly values the comprehensive risk rating” and has systems in place to monitor all risk metrics continuously. In 2022, the regulator conducted a SARMRA on-site assessment, with AXA Tianping scoring 72.82 (out of 100) – a reasonable score indicating effective risk management framework.

📊 Risk drivers. The minimum capital requirement (~¥1.1 b in 2024) arises from various risk modules: underwriting risk (especially motor risk charges), market risk, credit risk, and a small operational risk charge. Under C-ROSS II, the charge for motor insurance was adjusted (the comprehensive auto reform reduced premium risk but maybe increased reserve risk factor). AXA Tianping’s solvency Q4 report likely details that the majority of its required capital is for non-life underwriting risk, with motor being the largest component, followed by credit risk on investments. The company’s high solvency margin indicates it could support growth – indeed, it has room to expand premiums or absorb shocks while staying above 200%. Core capital consists of paid-up capital (¥846 m) and surplus and retained profits. The Tier 2 capital added is presumably a 10-year subordinated bond (common in China’s insurance market for solvency purposes). The presence of Tier 2 capital improved the comp ratio significantly in 2023, showing active capital management.

✅ Compliance status. In conclusion, AXA Tianping is safely capitalized under C-ROSS II. Solvency ratios consistently around 200%+ demonstrate a substantial cushion above regulatory minima. The regulator’s latest risk rating of “B” confirms the company meets all solvency and risk management requirements. There have been no regulatory red flags regarding solvency. In fact, group support ensures that if needed, AXA would inject capital to keep ratios healthy (though so far internal sub-debt has sufficed). The solvency outlook is stable – as the company moves toward profitability, capital will organically grow, further strengthening the ratios (S&P even revised AXA Tianping’s outlook to Positive in 2025 on expectation of improving capitalization and profitability). All solvency indicators thus reinforce confidence in AXA Tianping’s financial stability and regulatory compliance.

~*~

Capital allocation

💰 Dividend policy. AXA Tianping has not declared any dividends to its shareholder (AXA) in the past five years. Given the company’s net losses from 2018 through 2024 (e.g., losses of ¥151 m in 2019, ¥193 m in 2020, etc.), it had no distributable profits. Chinese regulations would in any case restrict dividends when solvency is below certain high thresholds or if the company is loss-making. Thus, 100% of earnings have been retained (or rather, losses absorbed by shareholder equity). The parent AXA has effectively left all capital in the entity to fund growth and improvement. Even prior to full ownership, Tianping only paid minimal dividends (if any) to its JV shareholders, as profits were modest. Post-2019, the expectation is that once AXA Tianping returns to profitability (projected by 2026), it may begin upstreaming dividends, but likely cautiously to support local growth. Until then, no dividend payouts have occurred – confirmed by the absence of any such disclosure in annual reports (the 2020–2024 reports do not mention dividend distributions, and retained earnings remain negative).

🏦 Capital support. AXA Group has provided capital support as needed to ensure solvency and growth funding. The major capital action was in 2014, when AXA’s initial entry included a RMB 2.0 billion capital increase into Tianping to bolster its growth. This raised the JV’s capital and supported nationwide expansion. In 2019, upon acquisition of the remaining 50%, rather than a new injection, AXA facilitated a capital reduction/buyback of ¥1.5 b (essentially cashing out the local shareholders), simplifying ownership. After the takeover, AXA Tianping’s registered capital stayed at ¥846 m, but AXA Group implicitly stood ready to inject if needed. During 2020–2024, no new common equity was injected by AXA, as solvency remained solid without it.

📉 Internal financing. Instead, capital was managed through internal arrangements. In 2023, AXA Tianping issued what appears to be a subordinated debt (capital supplementary bond) to add Tier 2 capital (we infer this from the jump in solvency ratio). While the exact details aren’t public in the disclosure, it’s common for insurers to issue a 10-year sub-debt counting as Tier 2. This issuance might have been subscribed by an AXA group entity or third-party investors. The amount was likely a few hundred million RMB. This move allowed the company to maintain solvency comfortably while still funding new business strain (especially from rapidly growing health premiums which require capital). No other external capital raises were noted.

🔄 Earnings retention. AXA has also effectively retained all earnings within the company (as noted, no dividends). In years where losses occurred, AXA did not require Tianping to cut back growth to conserve capital – instead, the group’s approach was to let the solvency ratio temporarily dip (to ~202% in 2022) and then adjust via the sub-debt. This indicates a balanced capital management: not over-capitalizing the entity (which would dilute ROE), but stepping in with support as needed. Looking ahead, if AXA Tianping needs additional capital for expansion (say, entering new business lines or if solvency falls due to rapid growth), AXA is expected to provide it. The NFRA requires advance approval for capital changes; there has been no report of denied capital plans. In 2021, for instance, the board had authorized the option of a capital injection or other financing if required, but it wasn’t utilized after assessing the solvency sufficiency.

🏗️ Growth investment. The capital that remains in the company has been used to fund the strategic pivot – e.g., investment in IT (capital expenditures for systems appear on the balance sheet as intangible assets), development of new products, and sales network expansion. Additionally, the capital base supports higher underwriting capacity. Notably, in 2022 the regulator allowed foreign P&C insurers to underwrite compulsory auto insurance across China, which meant AXA Tianping could use its capital to write that business nationwide (it was already doing so, but it underscores capital strength needed for regulatory approval). The capital allocation within the business has been towards growth rather than yield: the company did not engage in risky high-yield investments to deploy capital, instead keeping to safe assets. This aligns with AXA’s global focus on disciplined capital usage.

✅ Summary management. In summary, capital movements for AXA Tianping have been limited and conservative: no dividends out, no new equity in post-2019 aside from internal optimization via sub-debt. The parent has demonstrated support by allowing retention of earnings and facilitating subordinate financing. This has kept the solvency solid while enabling the company’s transformation. As losses taper off, retained earnings will begin to rebuild the equity base (for example, OCI gains already contributed significantly in 2024). It’s reasonable to expect that once profitable, AXA Tianping might pay moderate dividends to AXA, but given AXA’s strategic emphasis on growing in China, they will likely reinvest a significant portion to fuel further expansion in health and other lines. The capital management approach thus far has struck a balance between regulatory prudence and growth support, ensuring AXA Tianping always operates with capital above required levels and with the backing of a strong global parent.

~*~

Company timeline

⏳ Era 1 (2004–2012): Founding and Direct Sales Growth. Tianping Auto Insurance Co., Ltd. is established in Shanghai on December 31, 2004. It begins as a domestic insurer focused on auto insurance, known for pioneering direct sales and outsourcing non-core operations. Tianping grows its direct motor insurance business across 18 provinces with dozens of branches, serving millions of customers and ~¥2 billion premium by early 2010s. It builds a low-cost model leveraging call centers and online quotes, and becomes an attractive JV target for foreign insurers seeking a China P&C foothold.

🤝 Era 2 (2014–2018): The AXA Joint Venture. In February 2014, AXA acquires 50% of Tianping Auto Insurance, entering a JV with domestic shareholders. AXA pays ~RMB 1.9 b to buy shares and injects RMB 2.0 b new capital, raising Tianping’s capital and ownership to 50/50. The company is renamed “AXA Tianping P&C Insurance Co., Ltd.” and rebranded to reflect AXA’s identity. This is one of the first large foreign investments in China’s P&C sector. Under joint management, AXA Tianping continues as a top-20 P&C insurer in China. It ranks 15th by premium in 2017 with about €1 b (¥7–8 b) GWP. The business remains ~90% motor, and direct channel thrives (6th largest direct motor player). However, profitability is mixed – the company posts small losses or near break-even results (e.g., net loss ¥20 m in 2017, then a larger ¥275 m loss in 2018 amid intense motor competition). It expands branches to 25 provinces and ~93 sub-branches by 2018. AXA sees potential to fully implement its strategy if it has control.

🏢 Era 3 (2018–2019): Full Acquisition and Transition. AXA signs an agreement to acquire the remaining 50% of AXA Tianping for ¥4.6 b. This landmark deal, completed in December 2019, makes AXA Tianping a 100% AXA entity – the first wholly foreign-owned P&C insurer in China. Concurrently, a capital reduction of ¥1.5 b is executed to buy back the domestic shareholders’ shares, simplifying ownership. AXA’s CEO Thomas Buberl hails it as a unique platform to fully capture China’s P&C and health market growth. After regulatory approvals, the acquisition closes on Dec 13, 2019. AXA Tianping is fully consolidated into AXA’s financials from that date. The company ends 2019 with a net loss of ¥151 m, still largely motor-driven. A new strategic plan is drawn to pivot to health and improve profitability under full AXA control.

📉 Era 4 (2020–2021): Reform Shocks and Strategic Pivot. The Comprehensive Motor Insurance Reform launches Sept 2020, cutting premiums ~20% industry-wide and squeezing margins. At the same time, COVID-19 impacts claims frequency (down) and new car sales (dampening motor premium). AXA Tianping sees flat premium in 2020 and a net loss of ¥193 m. The company accelerates its digital initiatives during the pandemic – enabling remote sales and claims – setting the stage for future growth in non-motor lines. AXA Tianping’s premium drops ~20% to ¥5.94 b in 2021 due to the full-year effect of lower motor rates. The combined ratio worsens, leading to its largest net loss of ¥276 m. In response, management implements cost cuts and launches new health products to diversify income. Leadership change: Mr. Choi Dongjun (AXA Asia executive) serves as Chairman in 2021, and Ms. Zhu Yaming becomes CEO in May 2021, signaling focus on local market expertise and health insurance background. The company’s comprehensive risk rating remains acceptable (likely A or B). Despite the loss, AXA reaffirms commitment – no withdrawal of capital; instead the strategy (“Grow in Health, Fix Motor”) is doubled down.

🔄 Era 5 (2022–2023): Recovery and Leadership Renewal. Premium rebounds 2% to ¥6.07 b, as non-motor growth offsets motor stagnation. Net loss narrows to ¥175 m. Importantly, AXA installs new leadership: In September 2022, Ms. Zhu Shamiao is appointed Chairwoman (the first Chinese national in this role since JV days), and in December 2022, Mr. Zuo Weihao is appointed General Manager (CEO). Both have strong insurance backgrounds and are charged with executing the transformation. The regulator approves these swiftly, indicating confidence. Also in 2022, the C-ROSS Phase II framework takes full effect – AXA Tianping adapts and still reports solid solvency (~202%). GWP grows ~7% to ¥6.535 b, with health premiums surging; underwriting loss continues to shrink. Net loss is cut to ¥98.6 m. The solvency ratio jumps to 238% after a capital supplement (Tier 2 sub-debt). S&P upgrades AXA Tianping’s outlook, noting expectations of profit by 2025 and an improving combined ratio trend. AXA Tianping receives a B rating in the regulator’s comprehensive risk assessment in mid-2023, meeting standards. On the strategic front, the company spearheads a partnership with PICC (MoU in 2023–24) to collaborate on services and reinsurance, showcasing AXA’s intent to embed deeper in China’s market fabric.

🚀 Era 6 (2024–Future): Nearing Breakeven and Future Growth. Premium approaches ¥6.74 b (an all-time high), with non-motor ~45% of that by year-end. The net loss is only ¥66 m, a minor fraction of premium (about 1%), and Q4 may even have been profitable. Combined ratio ~106%. Solvency remains ~240%. The NFRA risk rating for Q3 2024 is “BB” (Category B), indicating a stable risk profile. AXA Tianping is poised to cross into profitability in 2025. The strategic pivot is largely accomplished in terms of business mix – health/lifestyle lines are driving growth. The company’s priorities now include scaling those lines efficiently and continuing digital innovation. AXA Group’s 2024 strategy update “Unlock the Future” emphasizes Asia growth, and AXA Tianping is a key part of that, expected to contribute positively going forward. Future plans likely involve expanding further into Green insurance (NEV vehicles), leveraging AXA’s global capabilities in climate and sustainability, and possibly exploring new channels (e.g., bancassurance partnerships via AXA’s global banking ties). With China’s regulator opening more scope for foreign insurers, AXA Tianping stands to benefit from any relaxation (like potentially seeking a life insurance license or deeper integration with AXA’s life JV, ICBC-AXA, in cross-selling). Throughout this timeline, it is notable that AXA’s support never wavered – even when AXA Tianping lost money for multiple years, AXA saw it as an investment in capturing the long-term opportunity. The full acquisition in 2019 and subsequent strategic investments have positioned AXA Tianping as a platform for AXA’s growth in China, now on the cusp of reaping rewards.

~*~